There is a question every serious nutraceutical formulator eventually confronts and that most of the industry quietly avoids.

If two products contain the same ingredients, why do they perform differently?

The answer, in most cases, is ratios.

The nutraceutical industry has developed a comfortable fiction that listing the right ingredients at broadly appropriate doses is sufficient for a clinically meaningful product. It is not. The ratio of one compound to another can determine whether two actives work together or against each other. It can determine whether a bioactive compound reaches the tissue where the patient needs it, or is degraded before getting there. It can determine whether a formulation actually solves the problem it claims to address.

At Makin Laboratories, ratio optimisation is not a manufacturing afterthought. It is where the real science of Nutraceutical Engineering begins.

The Silymarin Example

Consider a patient with liver stress. Their doctor recommends Milk Thistle, one of the most extensively studied nutraceutical ingredients in the world, with well-documented hepatoprotective properties backed by meta-analyses and over 20 clinical trials.

Yet clinical outcomes with Milk Thistle products vary enormously. The reason is almost never the ingredient itself. It is almost always the silymarin composition.

Silymarin is not a single compound. It is a family of flavonolignans, silybin A, silybin B, silychristin, silydianin, isosilybin A and B, and the ratio of these compounds to each other is not fixed. It varies by plant variety, growing conditions, extraction method, and processing temperature. Two products, both standardised to "70% silymarin," can have completely different ratios of silybin A to silybin B. These are compounds with different potencies, different bioavailability profiles, and different activities in the liver cell.

A formulator specifying only "70% silymarin" is not specifying a formulation. They are specifying a label. A Nutraceutical Engineering approach specifies the complete flavonolignan profile, the extraction method that achieves it, and the HPLC method that verifies it batch to batch because the patient's liver deserves that precision.

Synergy is Real But Not Automatic

The concept of formulation synergy, that combinations produce effects greater than any individual ingredient, is well established. What is less understood is that synergy is ratio-dependent.

Curcumin and Boswellia are widely combined for joint pain. Both have documented anti-inflammatory effects, and both are relevant to the patient's problem. But whether they actually work better together depends on the ratio of curcuminoids to AKBA, the form of curcumin used, and the Boswellia extraction specifications.

At Makin, these ratios are determined through in vitro testing, measuring the combined effect of different ingredient ratios on specific biological targets before committing to a formulation. This is the only way to know a combination is genuinely synergistic rather than just assumed to be.

What This Means for Intellectual Property

Specific ingredient combinations at specific ratios, validated for their mechanism of action, can be patented. A generic ingredient list cannot. This is the foundation of Makin's 12 patented formulations, protected not because they contain unique ingredients, but because the precise ratios and mechanism-specific targeting represent genuine innovation no competitor can legally reproduce.

For patients, that precision is the difference between a product that helps and one that merely contains the right names on the label.

Tags: Nutraceutical Engineering, Formulation Ratios, Silymarin, IP Protection, Nutraceutical Quality, Mechanism-Driven Formulation